Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome c oxidase assembly factor heme A:farnesyltransferase (COX10) (COX10)
- Target
- COX10
- Molecular classification
- Enzyme, Mitochondrial respiratory chain complex assembly factor
01
Overview
Cytochrome c oxidase assembly factor heme A:farnesyltransferase (COX10) is a mitochondrial inner membrane enzyme essential for the biogenesis of cytochrome c oxidase (complex IV), the terminal enzyme of the mitochondrial respiratory chain. COX10 catalyzes the farnesylation of protoheme IX (heme B) to produce heme O, and is indispensable for subsequent heme A synthesis – a prosthetic group essential for complex IV function. Mutations in COX10 impair heme A production, disrupt complex IV assembly, and lead to various mitochondrial diseases that manifest as neuromuscular, cardiac, or multi-systemic disorders of energy metabolism. COX10 is not itself a structural subunit of cytochrome c oxidase, but as a nuclear-encoded assembly factor, it is critical for generating the mature, functional holoenzyme required for efficient oxidative phosphorylation and ATP production.
- Other names
- Protoheme IX farnesyltransferase, mitochondrialHeme O synthaseCytochrome c oxidase assembly factor heme A:farnesyltransferase COX10COX10 homolog, cytochrome c oxidase assembly protein, heme A: farnesyltransferaseMC4DN3
02
Mechanism of action
Inhibition or genetic loss-of-function causes defective heme A synthesis, disrupting cytochrome c oxidase (complex IV) assembly, leading to impaired mitochondrial respiration and reduced ATP production
03
Biological functions
Heme biosynthesisElectron transport chain assemblyMitochondrial oxidative phosphorylationRegulation of cellular respiration
04
Disease associations
Mitochondrial disorders (incl. Leigh syndrome, hypertrophic cardiomyopathy, infantile mitochondrial myopathy)Neurodegenerative disease (Charcot-Marie-Tooth type 1A, hereditary neuropathy with liability to pressure palsies)AnemiaCardiovascular disease (hypertrophic cardiomyopathy)
05
Safety considerations
Mutations cause a spectrum of mitochondrial diseases often affecting the heart, muscle, or nervous system and presenting with symptoms such as ataxia, hypotonia, lactic acidosis, anemia, myopathy, hypertrophic cardiomyopathy, and sensorineural hearing lossLoss of function may lead to severe metabolic compromise, particularly in energy-demanding tissues
06
Biomarkers
Cytochrome c oxidase activity (complex IV deficiency)Heme A and heme O levels (functional assessment)Lactate (secondary to impaired oxidative phosphorylation)Genetic testing for COX10 mutations in suspected metabolic or neurological disorders
Beyond the preview
Go deeper on Cytochrome c oxidase assembly factor heme A:farnesyltransferase (COX10) (COX10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytochrome c oxidase assembly factor heme A:farnesyltransferase (COX10) (COX10).